RxDoctor Payments Data

Allysha Varughese, PA

Physician Assistant · Garden Grove, CANPI 1316430754

Payments from drug & device makers

$4,130in general payments, 2019–2025

Across 195 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$585
  • AstraZeneca$385
  • Abbott$322
  • Merck$310
  • Alnylam Pharmaceuticals Inc.$293
  • E.r. Squibb & Sons, L.L.C.$265
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,116100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,130 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$25,506
Medicare patients
186
Services billed
280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban394$335,310
EntrestoSacubitril/Valsartan104$96,694
XareltoRivaroxaban44$42,560
FarxigaDapagliflozin Propanediol34$36,288
Repatha SureclickEvolocumab39$30,367
Metoprolol Succinate182$2,642
Diltiazem 24hr Er (Cd)Diltiazem Hcl17$1,646
Rosuvastatin Calcium65$1,549
Flecainide Acetate32$996
Atorvastatin Calcium84$936
ClopidogrelClopidogrel Bisulfate101$880
Losartan Potassium106$825
Carvedilol94$556
Ezetimibe15$473
Metoprolol Tartrate67$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$335,310394 claims
NovartisEntresto$585$96,694104 claims
Johnson & JohnsonXarelto$107$42,56044 claims
AstraZenecaFarxiga$385$36,28834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Garden Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →